TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas

Rajeswaran Mani; Samon Benrashid; M. Templeton; Lawrence J. Druhan; Sara L. Seegers; Supriya Chakraborty; Sarah E Teague; Scott C Jaros; Hsih‐Te Yang; David Foureau; Nury Steuerwald; Dhananjaya Pal; Nilanjan Ghosh; Edward A. Copelan; Donald L. Durden; Belinda R. Avalos; Steven Park

doi:10.1016/j.isci.2025.112584

TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas

Rajeswaran Mani, Samon Benrashid, M. Templeton, Lawrence J. Druhan(Wake Forest University), Sara L. Seegers, Supriya Chakraborty, Sarah E Teague, Scott C Jaros, Hsih‐Te Yang, David Foureau, Nury Steuerwald, Dhananjaya Pal, Nilanjan Ghosh(Wake Forest University), Edward A. Copelan(Wake Forest University), Donald L. Durden(Wake Forest University), Belinda R. Avalos(Wake Forest University), Steven Park(Wake Forest University)

iScience

May 2, 2025

10.1016/j.isci.2025.112584

Cited by 2Open Access

Full Text

Abstract

. However, concurrent inhibition of Aurk restored the TP53/CDKN1A pathway, sensitizing the tumors to Bcl2 inhibitor-mediated apoptosis. These data lay the groundwork for evaluation of this combination in the clinical setting.

Related Papers

No related papers found

Powered by citation graph analysis